Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study.

"Declarations Ethics approval and consent to participateThis study was approved by the ethical committee of the First Affiliated Hospital of Zhejiang Chinese Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Conflict of interestThe authors declare no conflict of interest. Conflict of interest The authors declare no conflict of interest."

"Funding The present study was supported by the National Natural Science Foundation of China (No. 82174138), Zhejiang Scientific Research Fund of Traditional Chinese Medicine (No. 2020ZB085, No. 2022ZA059), and Health technology Plan of Zhejiang Province (No. 2022RC216), Project of Academic Inheritance Studio of Famous and Aged Chinese Medicine Experts in Zhejiang Province (No. GZS2021022)."

"The data of newly diagnosed AA patients in the First Affiliated Hospital of Zhejiang Chinese Medical University from January 2019 to July 2021 were retrospectively reviewed. The diagnosis and assessment of the disease were confirmed based on the Camitta criteria [] and 2015 BJH guidelines [], and the cases included severe aplastic anemia (SAA), very severe aplastic anemia (VSAA), non-severe aplastic anemia (NSAA), and transfusion-dependent none-severe aplastic anemia (TD-NSAA). Informed consent was obtained according to the Helsinki Declaration. This study was also registered at chictr.org.cn (# ChiCTR2100054992)."